固本止咳颗粒治疗咳嗽变异性哮喘临床研究

目的观察固本止咳颗粒治疗咳嗽变异性哮喘（CVA）的临床疗效，初步探讨其作用机理。方法将140例eVA患者随机分为治疗组和对照组，每组70例。治疗组予固本止咳颗粒口服，对照组予布地奈德粉吸入剂加硫酸沙丁胺醇气雾剂吸入，2组实施相同的护理干预。疗程8周，停药后随访8周。观察2组治疗前后、停药后8周时的咳嗽症状积分及治疗前后外周血嗜酸粒细胞计数（EOS）、血清免疫球蛋白E（IgE）含量的变化。结果治疗组完成67例，对照组完成66例。2组治疗后咳嗽症状积分、EOS及IgE均显著降低（P〈0．01，P〈0．05），治疗组咳嗽症状积分降低更明显（P〈0．01）。治疗组总有效率91．04％，复发率9．48％；对照组总有效率83．33％，复发率30．91％。治疗组总有效率优于对照组（P〈0．05），复发率低于对照组（P〈0．01）。结论固本止咳颗粒治疗CVA疗效显著且复发率低，良好的抗炎及抗变态反应作用可能是其治疗机制之一。

Clinical Study on Gubenzhike Granule in Treating Cough Variant Asthma

Objective To observe the clinical curative effect of Gubenzhike granule on cough variant asthma （CVA）, and explore its mechanism. Methods A total of 140 cases of CVA were randomly divided into two groups, 70 cases for each group. The treatment group took Gubenzhike granule orally, and the control group inhaled Budesonide Powder for Inhalation and Salbutamol Sulphate Aerosol, respectively for 8 weeks, with 8 weeks follow-up after treatment. The same nursing intervention was implemented in two groups. Cough symptom scores of the two groups were observed after treatment and at the end of follow-up, the number of eosnophils （EOS） and content of immunoglobulin E （IgE） in peripheral blood were also observed. Results The treatment group completed 67 cases and the control group completed 66 cases. After treatment, the cough symptom scores, EOS and IgE in two groups were significantly reduced （P〈 0.01, P 〈0.05）, and the cough symptom score of treatment group decreased more significantly than that of control group （P〈0.01）. The total effective rate and recurrence rate were 91.04% and 9.84% in treatment group, and 83.33% and 30.91% in control group. The total effective rate of treatment group was better than the control group （P〈0.01）, and the recurrence rate was lower than the control group （P〈0.01）. Conclusion Gubenzhike granule showed significant effect and low recurrence rate on CVA. Good anti-inflammatory and antianaphylaxis effects may be one of its mechanisms.